kpt-330

Small moleculeexperimental

Clinical trial activity

7 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
7
Phase 3
0
Phase 4
0

Earliest trial started Sep 1, 2017 (NCT03193437)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1
Mol. weight
443.31 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

First in class

Sources

Also known as

  • kpt-330
  • kpt-330
  • open label selinexor

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06822972Phase 2May 1, 2025Duke University
NCT05980806Phase 2Mar 31, 2024Karyopharm Therapeutics Inc
NCT05975944Phase 1/Phase 2 (Phase 2)Sep 30, 2023Tianjin Medical University
NCT06114004Phase 2Sep 28, 2023Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas, Universidad Autonoma de Madrid
NCT05850286Phase 2Apr 20, 2023China Academy of Chinese Medical Sciences
NCT05974085Phase 2Aug 1, 2022Chinese Academy of Medical Sciences
NCT03193437Phase 2Sep 1, 2017Georgetown University, Karyopharm Therapeutics Inc, Rutgers University
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Karyopharm Therapeutics IncFor profit2112017
Asociación Europea y Latinoamericana SELNET para la Investigación en SarcomasAcademic/Hospital1112023
China Academy of Chinese Medical SciencesAcademic/Hospital1112023
Chinese Academy of Medical SciencesAcademic/Hospital1112022
Duke UniversityAcademic/Hospital1112025
Georgetown UniversityAcademic/Hospital1112017
Rutgers UniversityAcademic/Hospital1012017
Tianjin Medical UniversityAcademic/Hospital1112023
Universidad Autonoma de MadridAcademic/Hospital1012023
9 organizations
Page 1 / 1